ArticleGland surgery2025
Survival benefit of surgery for inflammatory breast cancer patients.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammatory breast cancer (IBC) is considered as the most aggressive subtype of breast cancer. The purpose of this study is to evaluate the effect of surgical treatments on IBC patients. Methods: Based on propensity score matching (PSM) analysis, we evaluated the prognostic significance of surgical intervention in patients with IBC by Cox proportional hazard models. A subgroup analysis was conducted to evaluate the impact of surgical treatment on patients of various groups. Kaplan-Meier (KM) analysis and log-rank tests were used to compare survival in the matched population. Results: A total of 2,473 patients with IBC diagnosed between 2000 and 2020 were assessed from the Surveillance, Epidemiology, and End Results (SEER) database. There were 298 patients in the non-surgery group and 2,175 patients in the surgery group. In the multivariable Cox analysis, IBC patients treated by surgery showed higher overall survival (OS) rates [hazard ratio (HR) =0.50, 95% confidence interval (CI): 0.43-0.57, P<0.001]. After PSM, the multivariable Cox analysis revealed significant associations between age, race, node (N) status, estrogen receptor (ER) status, human epithelial growth factor receptor-2 (HER2) status, surgery, chemotherapy, and OS. Within the matched population analysis, patients derived significant benefits from surgery (HR =0.51, 95% CI: 0.42-0.62, P<0.001). Moreover, the OS outcomes of patients who received radiation therapy or chemotherapy in addition to surgical treatment were superior to those without surgery (chemotherapy, P<0.001; radiation therapy, P<0.001). Conclusions: IBC patients who were treated with surgery had better OS outcomes. Therefore, a multimodality approach is recommended for the management of IBC, which involves the use of surgical intervention as the main treatment modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.